Jefferies Group LLC Mersana Therapeutics, Inc. Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $43,997 - $77,460	-15,492 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $13,426 - $23,801	3,590 Added 30.16%	15,492 $0
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $65,222 - $117,353	11,902 New	11,902 $36,000
Q4 2019 Feb 13, 2020	SELL	$1.45 - $6.73 $36,999 - $171,729	-25,517 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$1.54 - $4.2 $18,054 - $49,240	11,724 Added 85.0%	25,517 $40,000
Q2 2019 Aug 14, 2019	BUY	$3.84 - $6.4 $52,965 - $88,275	13,793 New	13,793 $56,000
Q1 2019 May 15, 2019	SELL	$3.51 - $7.3 $1.18 Million - $2.45 Million	-336,238 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$3.45 - $9.72 $1.16 Million - $3.27 Million	336,238 New	336,238 $1.37 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $215M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.